Steven Abrams

Assistant Professor

University of Antwerp

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Steven Abrams is an Assistant Professor at the University of Antwerp, Belgium. His research encompasses a range of areas including Bayesian modeling of pathogenic infections, vaccine benefit-risk assessments, and the estimation of malaria transmission parameters. He has published extensively on topics such as children's roles in the COVID-19 pandemic, urban fuel usage in developing countries, and molecular screening for influenza. His contributions to the field are evident in his recent works focused on epidemic modeling and vaccine evaluations within the European Union.

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (17)

Sereina Annik Herzog

Assistentprofessor

Medical University of Graz

AUSTRIA

Steven Abrams

Research Interests

Explore related searches

Contact this professor

About

Articles (26)

Assessing the role of children in the COVID-19 pandemic in Belgium using perturbation analysis

Charcoal and firewood use in urban areas of developing countries: Drivers, consequences, and the need for clean cooking solutions

A Bayesian mixture model accounting for individual heterogeneity in response to pathogenic infection

An extension of the Benefit Risk Assessment of VaccinEs toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union

An integrative review of the combined use of mathematical and statistical models for estimating malaria transmission parameters

Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients

Systematic Molecular Influenza A/B Screening Upon Hospital Admission in Belgium, January-April 2022: Positivity Ratios and Viral Loads According to Symptomatology, Age, and Vaccination Status

Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study

Bernstein-based estimation of the cross ratio function

Who acquires infection from whom? A sensitivity analysis of transmission dynamics during the early phase of the COVID-19 pandemic in Belgium

Characterising information gains and losses when collecting multiple epidemic model outputs.

Dietary outcomes of community-based cardiovascular disease preventive interventions: a systematic review and meta-analysis

Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: A systematic review

Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies

Dietary outcomes of community-based cardiovascular disease preventive interventions: a systematic review and meta-analysis

A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant

A digital toolkit to contextualize and visualize the benefit and risk of COVID-19 vaccines in the European union

Evolution of human papilloma virus prevalence in a highly vaccinated region in Belgium: a retrospective cohort study in Flemish women (2010-2019)

The impact of national and international travel on spatio-temporal transmission of SARS-CoV-2 in Belgium in 2021

Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Correction: Dusabimana et al. Surveillance for Onchocerciasis-Associated Epilepsy and Ov16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening. <i>Pathogens</i> 2022, <i>11</i>, 281

Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6&ndash;10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening

Level of cardiovascular disease knowledge, risk perception and intention towards healthy lifestyle and socioeconomic disparities among adults in vulnerable communities of Belgium and England

Predicting mortality in intensive care unit patients infected with Klebsiella pneumoniae: A retrospective cohort study

A data-driven metapopulation model for the Belgian COVID-19 epidemic: assessing the impact of lockdown and exit strategies

Collaborators (17)

Sereina Annik Herzog

Ricardo Ewert

Philippe Beutels

Pieter Libin

Kristien J Ledeganck

Iuliu Sorin Pop

Yu-Chia Hsu

BENEDICTE DE WINTER

Inneke Van Nieuwenhuyse

Luc Bijnens

Alfred Dusabimana

Hamid Yimam Hassen

Pietro Coletti

Karl Martin Wissing

Degefaye Zelalem Anlay

Lander Willem

Hilde Bastiaens

Make your next move.

Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening